A Two-Sequence, Four-Period, Crossover, Full-Replicate Study to Demonstrate Bioequivalence of Carbamazepine Extended-Release Tablets in Healthy Subjects under Fasting and Fed Conditions

  • Shashank Salunke Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India
  • Ashish Birla Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India
  • Sandip Chaudhari Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India
  • Manasvi Makwana Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India
  • Kailash Waghmare Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India
  • Paresh Shah Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India
  • Sanjay Shelke Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India

Abstract

Carbamazepine is a first-line antiepileptic drug (AED) used for the treatment of partial and tonic-clonic seizures. We conducted an open label, balanced, randomized, two-treatment, two-sequence, four-period, single oral dose, full-replicate crossover study to assess and compare the  bioequivalence of  test  product  Carbamazepine extended release tablets USP 400 mg with reference  product Tegretol®-XR 400 mg (Carbamazepine extended release tablets), respectively in  healthy subjects under fasting and fed conditions. Blood samples were collected pre-dose and at regular intervals post-dose up to 240.00 hours. The plasma concentration was analyzed by a validated LC-MS/MS method and the reference-scaled and the unscaled procedure was used to determine bioequivalence for the pharmacokinetics parameters, Cmax, AUC0–t, AUC0-inf, Tmax, T½, Kel and AUC extrapolated was calculated. The results showed that the geometric mean ratios of Cmax, AUC0–t and AUC0-inf were 113.04%, 108.33% and 108.15% respectively, in the fasting conditions and 113.99%, 110.13% and 111.41%, respectively, in the fed conditions and the 90% confidence intervals were all within the range of 80.00% to 125.00%. It can be concluded from the result that the test product Carbamazepine extended release tablets based on osmotic release system (OROS) are bioequivalent to the reference product Tegretol®-XR tablets.


Keywords:  Bioequivalence, Carbamazepine, Sodium Channel Modulators and Epilepsy

Keywords: Bioequivalence, Carbamazepine, Sodium Channel Modulators and Epilepsy

Downloads

Download data is not yet available.

Author Biographies

Shashank Salunke, Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India

Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India

Ashish Birla, Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India

Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India

Sandip Chaudhari, Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India

Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India

Manasvi Makwana, Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India

Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India

Kailash Waghmare, Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India

Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India

Paresh Shah, Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India

Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India

Sanjay Shelke, Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India

Unique Pharmaceutical Laboratories, India (A Division of J. B. Chemicals & Pharmaceuticals Ltd.), Worli, Mumbai, India

References

1. Beghi E, Giussani G, Sander JW. The natural history and prognosis of epilepsy. Epileptic Disord. 2015 Sep; 17(3):243-53. PMID: 26234761. https://doi.org/10.1684/epd.2015.0751
2. World health organization, Epilepsy, Available at: https://www.who.int/news-room/fact-sheets/detail/epilepsy, Date [ 9 Feb 2022]
3. Goldenberg, Marvin M. "Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment." Pharmacy and Therapeutics 2010; 35(7):392
4. Tolou-Ghamari, Z., Zare, M., Habibabadi, J. M., & Najafi, M. R. A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2013; 18(Suppl 1):S81-S85
5. Dean L. Carbamazepine Therapy and HLA Genotype. 2015 Oct 14 [updated 2018 Aug 1]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. PMID: 28520367
6. Lo, J. Carbamazepine. Encyclopedia of Toxicology, 2014; 665-667. https://doi.org/10.1016/B978-0-12-386454-3.00705-3
7. Koester, Letícia & Costa, Teresa & Bassani, Valquiria. Pharmacokinetics of carbamazepine from extended release dosage forms: Bioavailability/bioequivalence and in vitro-in vivo correlation studies. Journal of Drug Delivery Science and Technology. 2004; 14:401-407. https://doi.org/10.1016/S1773-2247(04)50070-9
8. Thakker KM, Mangat S, Garnett WR, Levy RH, Kochak GM. Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients. Biopharm Drug Dispos. 1992 Nov; 13(8):559-69. PMID: 1421050 https://doi.org/10.1002/bdd.2510130802
9. FDA Draft Guidance of carbamazepine available at: https://www.accessdata.fda.gov/drugsatfda_docs/psg/Carbamazepine_ER%20tab_020234_RV03-15.pdf
10. Eckenhoff B, Theeuwes F, Urquhart J. Osmotically actuated dosage forms for rate-controlled drug delivery. Pharmaceutical Technology. 1981; 5(1):35-44
11. Gatlewar S, Meshram R, Gangane P, Mahapatra, D, Mahajan N. Rational Development of Carbamazepine Osmotic Controlled Release Oral Delivery System for Multiple Therapeutic Advantages. International Journal of Current Research and Review. 2020; 12:43-48. https://doi.org/10.31782/IJCRR.2020.122406
12. Santus G, Baker RW. Osmotic drug delivery: a review of the patent literature. Journal of Controlled Release. 1995; 35(1):1-21 https://doi.org/10.1016/0168-3659(95)00013-X
13. Verma RK, Garg S. Development and evaluation of osmotically controlled oral drug delivery system of glipizide. European Journal of Pharmaceutics and Biopharmaceutics. 2004; 57(3):513-525 https://doi.org/10.1016/j.ejpb.2004.02.003
Statistics
43 Views | 5 Downloads
How to Cite
1.
Salunke S, Birla A, Chaudhari S, Makwana M, Waghmare K, Shah P, Shelke S. A Two-Sequence, Four-Period, Crossover, Full-Replicate Study to Demonstrate Bioequivalence of Carbamazepine Extended-Release Tablets in Healthy Subjects under Fasting and Fed Conditions. JDDT [Internet]. 15Jun.2022 [cited 1Jul.2022];12(3-S):164-8. Available from: https://jddtonline.info/index.php/jddt/article/view/5404